Anika to Participate in the Sidoti Virtual Investor Conference
Anika Therapeutics (NASDAQ: ANIK), a leader in osteoarthritis pain management and regenerative solutions, has announced its participation in the upcoming Sidoti Virtual Investor Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Anika Therapeutics (NASDAQ: ANIK), a leader in osteoarthritis pain management and regenerative solutions, has announced its participation in the upcoming Sidoti Virtual Investor Conference. The company's management will deliver a virtual presentation followed by a Q&A session on Wednesday, May 21, 2025, at 1:00 PM ET. Investors can access the live webcast through Anika's Investor Relations website section at www.anika.com, where an archived version will also be available for later viewing.
Details
News Market Reaction – ANIK
The recorded move for ANIK in the trading session of this news was +1.73%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEDFORD, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that management will participate in the Sidoti Virtual Investor Conference on Wednesday, May 21, 2025. Anika will host a virtual presentation with Q&A starting at 1:00pm ET.
Webcast of the presentation and Q&A will be available in the Investor Relations section of Anika’s website, www.anika.com. An archive of the presentation will also be available on the website.
About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is the global leader in the design, development, manufacturing, and commercialization of hyaluronic acid (“HA”) innovations. In partnership with clinicians, our sole focus is dedicated to delivering and advancing osteoarthritis (“OA”) pain management and orthopedic regenerative solutions. At our core is a passion to deliver a differentiated portfolio that improves patient outcomes around the world. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.
ANIKA, ANIKA THERAPEUTICS and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.
For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Director, Corporate Development and Investor Relations
investorrelations@anika.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.